Denbinobin等化合物之抗血癌機轉探討

Abstract

多種抗癌藥物是源自於天然物成分或是天然物經過化學結構上的修飾而得，然後廣泛的使用在癌症的治療上。在本篇論文中，我們針對數種天然物和化學合成物進行作用機轉的探討，這其中包括萃取自傳統中草藥石斛(Dendrobium nobile)分離出的成分denbinobin及吳茱萸(Evodia rutaecarpa)的成分evodiamine，還有來自海洋生物珊瑚(Clavularia viridis)的clavulone II，這些成分過去曾被報導指出具有抑制癌細胞生長的效果，而TW01是個新合成的化合物，惟這些成分確切的作用機轉都並不清楚，因此促成了我們在人類白血病細胞上的研究。 第一部份，我們探究denbinobin對人類慢性骨髓性白血病K562細胞生長分化的影響。在24小時的作用下，denbinobin會隨著作用濃度的增加，抑制細胞的生長，其IC50濃度約為1.84

Natural products have long been an abundant source of therapeutic drugs and even today the natural products-derived anticancer compounds still contribute a lot to cancer chemotherapy. However, with a persistent increase of patients to cancer insults, there is a continuing need for development of new anticancer drugs. In the present dissertation, we examined the anticancer effects and elucidated the action mechanisms of several compounds in several human acute and chronic leukemia cells. Denbinobin (5-hydroxy-3,7-dimethoxy-1,4-phenanthraquinone) has been reported to exhibit anti-tumor and anti-inflammatory activity. We evaluated the anticancer activity of denbinobin in human myelogenous K562 leukemia cells. Denbinobin inhibited cell viability with an IC50 value of 1.84